Intalfa (interferon alfa 2b)
/ Intas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 15, 2014
Time for change: Conventional interferon regimes should not be the standard of care for management of Pakistani genotype-3 in chronic hepatitis C
(J Coll Physicians Surg Pak)
- P=NA, N=220; "Out of total cohort, 84.92% (169 out of 199) achieved end of treatment response (ETR) while 63.31% (126 out of 199) achieved sustained virological response (SVR). Leukopenia, gastrointestinal and miscellaneous systemic complaints were the most common adverse effects."
Clinical data • Hepatitis C Virus
1 to 1
Of
1
Go to page
1